Brian Alexander: Honored to participate in the NCI’s Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice
Brian Alexander, CEO of Foundation Medicine, shared a post by Foundation Medicine on LinkedIn, adding;
“Honored to participate in the National Cancer Institute (NCI)’s Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer.”
Qouting Foundation Medicine‘s post:
“Proud to announce our participation in the National Cancer Institute (NCI)’s Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer. This initiative is the largest of its kind to test the effectiveness of biomarker-targeted cancer treatment combinations to seek improvement in patient outcomes. Foundation Medicine is one of the largest contributors of potential participants to ComboMATCH, in connection with which Foundation Medicine testing results will help determine trial eligibility for patients. ”
Read more at the link here.
For the video attached to the post click here.
Source: Brian Alexander/LinkedIn and Foundation Medicine/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023